Uracil/tegafur plus oral calcium folinate in advanced breast cancer

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity agai nst breast cancer and is deliver-ed in an easy-to-administer oral formulati on Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide evert greater antitumor efficacy against breast cancer. Here, w e describe the preliminary results of this phase II trial investigating the feasibility of 250 mg/m(2)/day of UFT phs 45 mg/day of oral calcium folina te administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and art overall response ra te of 27.8% in a group of poor-prognosis patients. These findings warrant c ontinued investigation.